Effect of the monoclonal antibody TRC105 in combination with Sunitinib on renal tumor derived endothelial cells

Anti-angiogenic therapy is an important strategy to limit growth, development and expansion of solid tumors. However, resistance to VEGF-targeting agents may develop, due to activation of alternative pro-angiogenic pathways, indicating the need of multiple target strategy. Here we obtained tumor end...

Descripción completa

Detalles Bibliográficos
Autores principales: Brossa, Alessia, Buono, Lola, Bussolati, Benedetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978257/
https://www.ncbi.nlm.nih.gov/pubmed/29854307
http://dx.doi.org/10.18632/oncotarget.25206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978257/
https://www.ncbi.nlm.nih.gov/pubmed/29854307
http://dx.doi.org/10.18632/oncotarget.25206

Ejemplares similares